Select Page

Ebola vaccines

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVABN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

Anywaine Z et al.

The Journal of Infectious Diseases 2019 Jun 5;220(1):46-56. 

Safety, immunogenicity and risk–benefit analysis of rVSV- G-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

Bache Emmanuel Bache, Martin P Grobusch & Selidji Todagbe Agnandji

Future Microbiology 2020;12(2):85-106.

Ebola virus vaccine receives prequalification

Talha Burki

The Lancet 2019; 394.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

Callendret B, Vellinga J, Wunderlich K et al.
PLoS One 2018; 13(2): e0192312.

Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone

Camacho A, Eggo RM, Goeyvaerts N et al.
Vaccine 2017 Jan 23;35(4):544-551. 

Vaccination of contacts of Ebola virus disease survivors to prevent further transmission

Doshi RH et al.
The Lancet Global Health Dec 2020; 8. 

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV

Ehrhardt SA, Zehner M, Krähling V, et al. 
Nature Medicine 2019 Oct;25,1589–1600.

Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

Goldstein N, Bockstal V, Bart S et al.
The Journal of Infectious Diseases 2020; jiaa586. 
Last updated: Mar 29, 2021

Make a donation now

By supporting NESI you are contributing to “Saving lives through immunisation”.

Share This
Skip to content